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Competition within the immune system may degrade immune control of viral infections. We
formalize the evolution that occurs in both HIV-1 and the immune system quasispecies. Inclusion
of competition in the immune system leads to a novel balance between the immune response and
HIV-1, in which the eventual outcome is HIV-1 escape rather than control. The analytical model
reproduces the three stages of HIV-1 infection. We propose a vaccine regimen that may be able to
reduce competition between T cells, potentially eliminating the third stage of HIV-1.
PACS numbers: 87.10.+e, 87.15.Aa, 87.17.-d, 87.23.Kg
Our immune system is highly effective in suppressing
most viral infections, due to the many different T cells
that exist in the repertoire of one person. While many
different T cells can recognize a virus, only those of high-
est affinity respond in large numbers and participate in
eliminating the virus. One limitation of our immune sys-
tem stems from the competition among T cells of similar
specificity for the virus. For a series of discrete infec-
tions over time, competition in the immune system is
associated with the phenomenon of deceptive imprinting
[1], or original antigenic sin, and has been characterized
by a random energy model [2]. Original antigenic sin is
the tendency for memory immune cells produced in re-
sponse to a first viral infection to suppress the creation of
new immune cells in response to a second infection with
a related strain. Moreover, while they are used, these
memory immune cells may not be optimal for control of
this second, different viral strain. Another form of com-
petition in the immune system occurs when several viral
strains simultaneously infect one person. In this case,
the T cells compete to recognize the different strains, and
recognition of all strains may not be uniformly effective.
This immunodominance of one strain over others means
that the immune response to multiple infections is not a
simple superposition of the responses to each individual
infection [3].
For a chronic infection with a mutating virus, the ef-
fects of competition are more subtle. Since the infection
changes slowly over months or years, there may be no
apparent original antigenic sin, as the immune system
slowly updates itself in an attempt to clear the virus. If
the virus evolves mainly through point mutation, the mu-
tants will be only slightly different from their parents and
can still be eliminated by the memory T cells. Moreover,
whenever a sufficiently new viral strain emerges through
the accumulation of point mutations that cannot imme-
diately be cleared by the immune system, there is enough
time for the immune system to create new T cells against
the new strain since the infection is chronic. Therefore,
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FIG. 1: The entire time course of HIV-1 infection. The circles
are clinical data from [4]. The solid line is generated by our
model.
competition might represent a relatively small weakness
of the immune system against chronic infections. How-
ever, when facing HIV-1, any trivial weakness may be-
come the immune system’s Achilles’ heel. A typical HIV-
1 infection is characterized by three phases. See Fig. 1.
The viral load initially increases dramatically in the first
viremia, followed by a sharp decline due to immunologi-
cal control. Thereafter, a long period of clinical latency
lasts for 6–10 years with small viral load. Finally, the
HIV-1 viral load climbs up again in the final viremia, in
the onset of AIDS. Most modeling works focus on the first
viremia (e.g., [5, 6]). In [7], the second and third stages
were modeled but without the first stage. The entire time
course has been difficult to reproduce faithfully by a uni-
fied mathematical model, probably due to the disparate
dynamics of the three phases. To describe each phase,
a different set of parameters has been given. The three
stage dynamics is reproduced by computational models
in [8, 9], but the mapping between parameters and phys-
2iology remains to be fully established in those models
[10].
In this letter, we develop an analytical, physical the-
ory of the immune response that explains HIV-1 patho-
genesis. A key concept in the model is a population of
viruses with different sequences that arise due to viral
evolution, termed the viral quasispecies. Since HIV-1
and the immune system are well-matched competitors,
the viral quasispecies and its dual, the lymphocyte qua-
sispecies, should be equally well matched. These con-
siderations lead to a theory with a large number of dy-
namical equations, which is reduced to a low dimensional
model by symmetry. The model fits well with the stan-
dard HIV-1 data of the entire infection time course, and
the parameters are all biologically reasonable. A novel
equilibrium between the immune system and virus qua-
sispecies is found, which, instead of fixing the viral load,
favors viral escape.
We let Vi (i = 0, 1, · · · I − 1) denote the HIV-1 quasis-
pecies i. We let vi denote the concentration, or load, of
Vi. We let v =
∑I−1
i=0 vi denote the total viral load. We
let Xi denote the T cell, or effector T lymphocyte, that
is specific for Vi. We let xi denote the concentration of
this T cell, and we let x =
∑I−1
i=0 xi denote the total T
cell concentration. We let kji denote the affinity between
the T cell Xj and the virus Vi. As a fairly generic as-
sumption, we take kij = exp(−βdij), where dij = dji is
the Hamming distance between Vi and Vj . Since roughly
two amino acid substitutions still permit recognition, we
expect β to be on the order of 1/2. The kij (i 6= j) repre-
sent cross-reactivities, which are generally beneficial for
the immune system because they offer additional killing.
However, the side effect of cross-reactivity is that it in-
duces competition when the T cells expand in concentra-
tion during the activation phase of the immune response.
We first hypothesize an ideal immune system that has
the following properties: (i) There is no competition
among the different T cells. This allows for the free de-
velopment of effector T cells whose total concentration
will reach its maximum capacity, x =
∑I−1
i=0 xi = 1. For
a realistic system, we will find x < 1 due to competi-
tion. (ii) There is no bias toward any viral quasispecies
in generating its corresponding effector cells. Therefore
one has xi/x = vi/v. Since x = 1, one has xi = vi/v.
The real immune system and the competition induced
in the response to HIV-1 are modeled as follows. Com-
pared to cytotoxic T cell lymphocytes (CTLs), antibodies
are much less effective in controlling HIV-1. Therefore,
we focus on the CTL responses, and a virus is accordingly
identified by its epitope that stimulates CTLs. The epi-
tope is N = 8–11 amino acids long, and in our model we
assume N = 9. The initial strain of virus is denoted by
V0. The assumption of an unique initial strain is based
on the bottleneck effect [11] and the reversion effect due
to lack of CTL pressure at infection [12]. We assume that
at each of the N sites on the epitope there are A possible
amino acid substitutions. The quasispecies space size is
thus I = (A + 1)N . We use A = 2 because each site can
accept few substitutions to keep the virus viable. We find
that the simulation results are not sensitive to A. The
subscript of Vi is in the range 0 ≤ i ≤ (1 + A)
N − 1
and can be written in form of a A + 1-radix number
i = (aN , aN−1, · · · , a1), with 0 ≤ an ≤ A. The Hamming
distance between epitopes is dij =
∑N
n=1(1 − δain,a
j
n
),
where δlm is the Kronecker delta. The model is
dvi
dt
= rivi −mNAvi +mΓi − c1fi(x)vi (1)
dxi
dt
= λ
(vi
v
− xi
)
− c3gi(x)xi, (2)
for i = 0, 1, · · · I − 1, with the initial condition v0(0) 6=
0, vi6=0(0) = 0, and xi(0) = 0. Previous models have
assumed linear suppression (fi = const) and not tracked
both viral and T cell quasispecies evolution [5].
In Eq. (1), ri = r0 exp(−αdi0) is the replication
rate of Vi. The wild type V0 replicates the fastest,
and mutation away demands some fitness cost. The
term m is the rate of mutation of the amino acids
at any one of the N sites into any one of the other
A amino acids (per amino acid per day). The term
mNAvi thus represents mutation away from qua-
sispecies i to its NA neighbors (efflux). The term
mΓi represents the reverse process (influx), where Γi =∑A
j=0
(
v(j,aN−1,...,a1) + v(aN ,j,...,a1) + . . .+ v(aN ,aN−1,...,j)
)
−
Nvi is the sum over all viral species a unit Hamming
distance away from i. The term fi(x) = yi(x)/[c2+yi(x)]
represents the lysis ratio of targeted cells harboring
Vi, where yi(x) =
∑I−1
j=0 xjkji =
∑I−1
j=0 xj exp(−βdji)
The derivation of fi(x) follows as in [13] by treat-
ing the competitive binding process as a Langmuir
adsorption isotherm of the CTLs onto targeted cells
that are infected with Vi. The concentration and
affinity here are dimensionless, while in [13] their
physical values {xj} and {kji} are used. That is,
fi(x) =
∑
j{xj}{kji}/[1 +
∑
j{xj}{kji}]. We let
{x}max and {k}max denote the maximum values of
concentration and affinity, respectively. We, thus, obtain
c2 = 1/({x}max{k}max). Typical concentrations are on
the order of 10−6 mol/l, typical binding constants are
on the order of 106 l/mol, and so we expect c2 to be on
the order of unity. Indeed, to fit clinical data, we will
find c2 = 0.8. The coefficient c1 is the rate of clearance
of virus released from targeted cells that are being lysed,
and to fit clinical data, we will find c1 = 4.0 day
−1, close
to a previous estimation of 4.3 day−1 [14].
The first part of the right hand side of Eq. (2) repre-
sents a delay process with time constant 1/λ, since the
immune system always lags in response to viral changes.
The term vi/v, which equals xi in an ideal immune sys-
tem, now serves as the moving target for xi to catch.
Moreover, the tracking of the virus by the immune sys-
tem is disturbed by the competition c3gi(x)xi, where
3gi(x) =
∑
j 6=i xjkji = yi(x) − xi represents competition
from the other T cells. This term has been used in study-
ing the competition within an ecosystem [15]. The T cells
that develop intoXi, must be stimulated by Vi. However,
since Xj (j 6= i) can occupy Vi, a delay in the maturation
of the T cell precursors into Xi can occur.
The number of non-linear equations in the model is
2(A + 1)N = 39366, which is difficult for analysis and
computation. However, there is apparent symmetry in
these equations: vi = vj and xi = xj as long as di0 = dj0.
That is, all the viruses that have an identical distance to
the wild type have the same dynamics and can be put into
the same group. We let v˜n (x˜n) denote the number of
elements in the viral (CTL) group n, one has v˜n = Q
n
Nvi
and x˜n = Q
n
Nxi for any i satisfying di0 = n, where Q
n
N =
CnNA
n and CnN = N !/[n!(N−n)!]. By substituting v˜n and
x˜n into Eqs. (1, 2) and noting that Γi = (n/Q
n−1
N )v˜n−1+
[n(A− 1)/QnN ]v˜n + [(N − n)A/Q
n+1
N ]v˜n+1, one obtains
dv˜n
dt
= mA (N − n+ 1) v˜n−1 +m (n+ 1) v˜n+1
+
(
γ0 exp (−αn)− c1f˜n (x˜)
)
v˜n
−mA (N − n+ n/A) v˜n (3)
dx˜n
dt
= λ
(
v˜n
v
− x˜n
)
− c3y˜n (x˜) x˜n +
c3
QnN
x˜2n (4)
for n = 0, 1, · · · , N , where f˜n(x˜) = y˜n(x˜)/[c2 + y˜n(x˜)].
To obtain y˜n(x˜) from yi(x), the following two steps are
performed. The first step is to rearrange the equation for
yi by summing up all the xj that have the same dji = n
′,
namely to obtain y˜n(x˜) =
∑N
n′=0 qn′ exp(−βn
′). To
be specific, let us consider i =

0 · · · 0︸ ︷︷ ︸
N−n
11 · · ·1︸ ︷︷ ︸
n


with d0i = n and a specific dji = n
′, j must sat-
isfy n − n′ ≤ dj0 ≤ n + n
′. To obtain a j with
dji = n
′ and dj0 = k, some 0’s or 1’s in this expres-
sion for i need to be changed, and the number of
ways to realize this is
∑n′
l=k−n Q
l
N−nC
l1
n P
l2
n−l1
, where
QlN−n = C
l
N−nA
l corresponds to changing l of the 0’s
into non-0; Cl1n corresponds to flipping l1 of the 1’s
into 0; P l2n−l1 = C
l2
n−l1
(A − 1)l2 corresponds to changing
l2 of the remaining (n − l1) 1’s into digits other than
0 and 1. The restrictions are l + l1 + l2 = n
′ and
n + l − l1 = k, from which one solves l1 = n + l − k
and l2 = n
′ − n + k − 2l. Therefore one obtains qn′ =∑n+n′
k=n−n′(x˜k/Q
k
N )
∑n′
l=k−n Q
l
N−nC
n+l−k
n P
n′−n+k−2l
k−l .
The second step is to sum up all terms that have the
same x˜k. That is, to obtain the matrix Φnk that is
defined by y˜ = Φx˜. By substituting the expression
of qn′ into the expression for y˜n one obtains Φnk =∑N
n′=0[exp(−βn
′)/QkN ]
∑n′
l=k−nQ
l
N−nC
n+l−k
n P
n′−n+k−2l
k−l .
The model parameters are determined as follows. The
termmA is the mutation rate per amino acid site per day.
The conventional HIV-1 mutation rate µ ≈ 2.2× 10−5 is
per nucleotide base per replication [16]. Given that one
replication cycle is about one day, one amino acid has 3
nucleotide bases, and about 3/4 nucleotide mutations are
nonsynonymous, one hasm = 3µ×0.75/A ≈ 2.475×10−5
per amino acid per day. The other parameter values are
estimated by fitting the standard data given by [4]. The
viral load data is in terms of the plasma HIV-1 titer,
which is two raised to the number of serial ×1/2 dilutions
that result in undetectable virus. In the first viremia
phase, the mutation has not yet taken significant effect,
Eqs. (1,2) can be simplified as v˙0 = r0v0 − c1x0v0/(c2 +
x0) and x˙0 = λ(1 − x0). Since the CTL response peaks
(i.e., x0 approaching 1) at 9 to 12 weeks after the initial
infection [17], we calculate from x˙0 = λ(1 − x0) that λ
is 0.033 day−1. By noting that the first viremia peaks
roughly at week 6 with plasma virus titer reaching 630
and declines by week 12, we find v0(0) = 3.7×10
−7, r0 =
1.88 day−1, c1 = 4.0, and c2 = 0.8. The fitting of the
latency and the final viremia phases requires α = 0.41,
β = 0.58, and c3 = 9.56×10
−2. As discussed above, only
α and c3 lack comparison to literature values.
Eqs. (3, 4) are still difficult for analysis because v shows
up in the denominator of Eq. (4). By summing Eq. (3)
over n, one obtains
dv
dt
=
N∑
n=0
(
γ0 exp(−αn)− c1f˜n(x˜)
)
v˜n. (5)
By defining p˜n = v˜n/v and plugging dv˜n/dt = vdp˜n/dt+
p˜ndv/dt into Eq. (3), one obtains
dp˜n
dt
= mA(N − n+ 1)p˜n−1 +(
γ0 exp(−αn)− c1f˜n(x˜)
)
p˜n
−mA(N − n+ n/A)p˜n +m(n+ 1)p˜n+1
−p˜n
N∑
n′=0
p˜n′
(
γ0 exp(−αn
′)− c1f˜n′(x˜)
)
(6)
dx˜n
dt
= λ(p˜n − x˜n)− c3y˜n(x˜)x˜n +
c3
QnN
x˜2n, (7)
which are regular nonlinear ODEs. By integrating the
above equations we find that p˜n(t) and x˜n(t) approach
the fixed point (p¯n, x¯n) as early as day 600. The eigenval-
ues of the Jacobian matrix evaluated at the fixed point
are all negative, indicating that the fixed point is sta-
ble. That is, an equilibrium has been reached between
the HIV-1 quasispecies and the immune system T cell
quasispecies. This result holds even as the viral load it-
self increases exponentially. All quasispecies escape at
the same rate, with their relative proportions fixed. To
calculate the rate of escape, Eq. (5) is converted into
v˙(t) = ε(t)v(t), where
ε(t) =
N∑
n=0
p˜n
(
γ0 exp(−αn)−
c1
∑
k Φnkx˜k
c2 +
∑
k Φnkx˜k
)
. (8)
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FIG. 2: The escape rate ε¯ increases as the competition c3
increases.
Because the viral quasispecies converges, ε(t) will even-
tually converge to a constant ε¯. Replacing (p˜n, x˜n) by
the fixed value (p¯n, x¯n), one obtains ε¯ = 0.0066 day
−1.
Because the equilibrium begins early, we conclude that
the majority of latent phase, which was previously mys-
terious, follows the same simple dynamics as the final
viremia phase. This result explains the observation [18]
that the lifespan of HIV patients is inversely correlated
with the minimum viral load vmin that happens at about
day 150 and is a direct result of the primary immune re-
sponse. Because the onset time to the final phase scales
as t ∝ − ln vmin/ε¯, the smallness of ε¯ significantly ampli-
fies the life span dependence on vmin.
By incorporating immune competition, we now have a
physical theory based upon an analytical model. Upon
infection, the virus proliferates with a large rate around
1.88 day−1, because the immune response has not been
fully established. At about week 6, the immune sys-
tem brings the virus down to a trace level. However,
the ever increasing viral genetic diversity induces com-
petition among CTLs, which degrades the quality of im-
mune control. Both a viral and a T cell quasispecies are
established. The concentrations of different CTLs be-
come fixed, as well as the percentages of different viral
quasispecies. However, the virus escapes exponentially.
Interestingly, it is this underlying pair of quasispecies
that drives the seemingly nonequilibrium process. While
small, c3 has become the Achilles’ heel of the immune
system. Competition among T cells may exert a small
influence for many diseases, but is fatal for HIV-1.
Our analysis predicts that competition among CTLs
has a pivotal role on viral dynamics. The function
ε¯ = ε¯(c3) is shown in Fig. 2. One sees that as c3, or the
level of competition, increases, the escape rate ε¯ increases
significantly. For the ideal immune system, c3 = 0 and
ε¯ = −0.0065, suggesting that the ideal immune system
can control HIV-1 infection. Even for the real immune
system, the smallness of |ε¯| implies that HIV-1 and the
immune system are well-matched competitors. When all
antigens are simultaneously present, competition among
T cells for activation and division occurs, and c3 is large.
By vaccinating to different lymph nodes with the differ-
ent HIV antigens likely to occur, competition between T
cells is reduced, and T cells that recognize each of the
different antigens may be produced at high concentra-
tion [3], and so c3 ≈ 0. In this case the virus never rises
again after week 12. The regimen should be designed
such that its components are given according to the fixed
viral quasispecies. According to our simulation, the final
viral percentages other than p˜0 and p˜5 are negligible. As
for sensitivity to the parameters, if α or β are increased,
in which case the data of Fig. 1 are not fit so well, p˜6
also becomes non-negligible. We thus propose a vaccine
regimen that includes not only the wild type but also
the p˜5 quasispecies. This vaccine must be given before
the eventual evolution of the quasispecies viral strains to
avoid immunodominance. If the vaccine were given after
evolution of the p˜5 species, then competition would be
unavoidable due to prior exposure of the immune system
to the multiple viral strains.
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